14 results about "Psoriasis patient" patented technology

The invention discloses a method and a system for constructing an intelligent typing diagnosis model of psoriasis. The method comprises the following steps: S1, collecting pairing multi-modal data of a psoriasis patient whose fingernails are not tired, wherein the pairing multi-modal data comprises clinical information, scanning electron microscope images of fingernail surface morphology and infrared spectrum data of fingernail protein; s2, constructing a clinical feature encoder; s3, constructing a spectral feature encoder; s4, constructing an image feature encoder; s5, constructing a hierarchical fusion module; and S6, three loss function components are constructed, multi-objective optimization of the model is realized, and a total loss function is adopted to carry out model training. According to the method, the clinical information, the scanning electron microscope image of the nail surface morphology and the infrared spectrum data of the nail protein are integrated, and the multi-mode deep learning technology is combined, so that early recognition and prediction of psoriatic arthritis in a psoriasis patient are realized.

The invention provides an oral medicine formula for treating psoriasis, and relates to the field of traditional Chinese medicine formulas. The oral medicine for treating psoriasis is prepared from the following raw materials by weight: 10 g of astragalus membranaceus, 50 g of rhizoma smilacis glabrae, 10 g of salvia miltiorrhiza, 10 g of cassia twig, 10 g of cicada slough, 10 g of ligusticum wallichii, 30 g of angelica sinensis and 10 g of honey-fried licorice root. Salvia miltiorrhiza, ligusticum wallichii, angelica sinensis and other medicines have the effects of promoting blood circulation to remove blood stasis, can improve the blood circulation state of skin and promote repair of skin lesions, and have a certain curative effect on blood stasis type psoriasis patients; cassia twig and cicada slough have the effects of dispelling wind and arresting itching, can relieve the symptom of skin itch, and improve the life quality of patients; astragalus membranaceus, angelica sinensis and honey-fried licorice root have the effects of reinforcing qi and nourishing blood, can improve the overall physique of a patient, enhance the immunity of the body and contribute to disease recovery, the clinical effective rate reaches 70% or above, one treatment course lasts for three months, and the cure rate can reach 40% or above.

The invention discloses a disease control state evaluation system and method based on psoriasis patient feedback, subjective feelings of patients on disease control can be captured in clinical and non-clinical scenes, and a concept framework is based on literature and doctor-patient feedback. Different from the past psoriasis PROM, the invention provides a method for comprehensively, standardly and quickly collecting'disease control 'information, and the structure content has value for clinical and scientific research. Statistical analysis shows that good clinical benefits can be obtained when the model is applied clinically, and an effective basis for individualized precise treatment is provided for improvement and self-management of psoriasis, especially chronic diseases in China.

The method of the embodiment of the present application proposes a method and a public platform for dynamically predicting the risk of osteopenia of psoriasis patients. First, high-quality data are screened from the historical medical records, bone density data and biomarker data of the patients, and multi-modal feature extraction is performed. The high-order interaction of the features of each mode is captured through a graph attention network to realize multi-modal feature fusion. Then, a deep attention neural network is constructed to realize the probabilistic prediction of the risk of osteopenia of psoriasis patients. Next, the individual prediction results are visualized and explained by using the model attention weight and SHAP value, thereby enhancing the clinical usability. Subsequently, the network is compressed and optimized through model distillation, pruning and quantization, thereby realizing the efficient deployment of the model on the edge computing device. Finally, the model parameters are continuously optimized in combination with the actual clinical results and the feedback of doctors. The present application effectively improves the accuracy of risk prediction.

The application discloses application of C1Q and / or its subunit as a target point in prevention and treatment of psoriasis. The C1QA / B / C gene expression in monocytes / macrophages in psoriasis lesions is enhanced, and there is a significant difference in the C1Q subunit protein content in serum of psoriasis patients before and after treatment, and the expression level of the C1Q subunit protein in serum of the psoriasis patients is significantly decreased after treatment. In addition, the knockout of the C1Q gene can effectively reduce the expression of psoriasis-related inflammatory factors such as IFN-gamma and TNF in monocytes with the C1Q gene knocked out, which indicates that by inhibiting the expression or function of the C1Q, the immune response and the inflammation level of the psoriasis patients can be regulated, and an effective prevention and treatment effect on the psoriasis can be achieved. Therefore, the C1Q can be applied to preparation of a medicine for preventing and treating the psoriasis as a biological treatment target point of the psoriasis.

The invention belongs to the technical field of biology, and particularly relates to a psoriasis treatment preparation and method and application. The expression of SECTM1 in the skin of a psoriasis patient is increased, an SECTM1 antibody can inhibit immune cells and relieve inflammatory response, psoriasis mice treated by the SECTM1 antibody can cause expression reduction of inflammatory factors Il6, Tnfa, Il1b, Il22 and Il17a, psoriasis skin treated by the SECTM1 antibody can cause reduction of CD7 + cell infiltration quantity, and hacat cells knock down SECTM1 gene expression so as to inhibit proliferation of skin epithelial cells, so that the SECTM1 antibody can be used for treating psoriasis mice. Therefore, the SECTM1 antibody preparation can be used for treating psoriasis, and the recurrence rate is low.

This invention provides an apremilast-loaded hydrogel of *Callicarpa nudiflora* vesicles, its preparation method, and its application, relating to the field of pharmaceutical formulation technology. This invention utilizes *Callicarpa nudiflora* vesicles to encapsulate apremilast and then reconstitute it into a hydrogel, preparing a drug that can be directly applied to the affected skin of psoriasis patients via local transdermal administration. The hydrogel achieves synergistic treatment of psoriasis through apremilast and *Callicarpa nudiflora* vesicles, improving efficacy.

The invention relates to a psoriasis diagnosis marker and a psoriasis treatment target, and relates to the technical field of biological medicines. Through systematic analysis on the number, area and diameter of lymphatic vessels and VEGF-C expression of psoriasis skin and an established mouse model, the invention reveals that VEGF-C expression in psoriasis patient skin is up-regulated, the number, area and diameter of lymphatic vessels are obviously higher than those of healthy control, and the number expression of lymphatic vessels in a mouse recurrence model is further increased; and the VEGF-C expression is further improved. The research of the invention provides a new diagnostic marker and a potential therapeutic target for psoriasis, and provides a new direction and strategy for treating psoriasis or preventing relapse of psoriasis.

The present invention relates to a biomarker composition for diagnosing psoriasis, comprising a Clostridium leptum strain as an active ingredient. It has been confirmed that the relative intestinal abundance of the strain is significantly reduced in a psoriasis patient group in comparison to that of a normal group, and the strain is effective in alleviating psoriasis symptoms and improving intestinal permeability, and thus can be effectively used as a composition for diagnosing, preventing, treating, or alleviating psoriasis.

This invention discloses the application of lupinone in the preparation of drugs for treating psoriasis, belonging to the field of pharmaceutical technology. In this invention, lupinone is used to treat psoriasis by regulating CD4 levels in psoriasis patients. + FoxP3 + The number of Tregs, regulatory T lymphocytes, reduces the expression of CD3-positive cells and the level of inflammatory factors in the skin lesions of psoriasis patients, thereby regulating the immune response of psoriasis patients and thus achieving the treatment of psoriasis. Specifically, it can reduce the severity of psoriasis, improve the degree of erythema, scaling and infiltration of skin lesions, significantly reduce the PASI (Psoriasis Area and Severity Index) score of skin lesions, reduce the thickness of the epidermis at the skin lesion site and inhibit epidermal proliferation, improve hyperkeratosis and parakeratosis, and improve acanthosis.

The present invention relates to use of C1Q and / or a subunit thereof as a target in the prevention and treatment of psoriasis. The C1QA / B / C gene expression in monocytes / macrophages in psoriatic skin lesions is enhanced, the content of C1Q subunit protein in the serum of psoriasis patients exhibits a significant difference before and after treatment, and the expression level of C1Q subunit protein in the serum of psoriasis patients after treatment is significantly reduced. In addition, the C1Q gene knockout can effectively reduce the expression of psoriasis-related inflammatory factors such as IFN-gamma and TNF in C1Q gene-knockout monocytes, indicating that by inhibiting the expression or function of C1Q, the immune response and inflammation level in psoriasis patients can be regulated, thus achieving effective prophylactic and therapeutic effects on psoriasis. Therefore, C1Q can be used as a biological treatment target for psoriasis to prepare a medicament for the prevention and treatment of psoriasis.

The invention belongs to the technical field of medicines, and particularly relates to application of an m6A methyltransferase METTL7A antagonist or inhibitor in preparation of a medicine for preventing and / or treating inflammatory skin diseases. According to the application disclosed by the invention, by analyzing RNA (Ribonucleic Acid) sequencing data of neutrophil of a psoriasis patient and a healthy control, remarkable high expression of the METTL7A gene in the neutrophil of the psoriasis is disclosed. QRT-PCR and Western Blot experiments further prove that the expression level of METTL7A in neutrophil of a psoriasis patient is remarkably up-regulated, and cell experiments show that METTL7A knockout can inhibit neutrophil activation and pro-inflammatory phenotype, which indicates that METTL7A participates in immunoregulation of inflammatory diseases such as psoriasis. A psoriasis mouse model experiment proves that the maturation and aging processes of neutrophils can be effectively delayed by knocking out METTL7A expression, so that the improvement or treatment of psoriasis is realized.

The invention provides application of alpha-linolenic acid to treatment of psoriasis by adjusting gamma delta T cells, and belongs to the technical field of biological medicine. The invention provides an application of alpha-linolenic acid (ALA) in preparation of a medicine for treating psoriasis, and after ALA intervention, the skin lesion severity of a psoriasis animal model is obviously reduced, the spleen index is obviously reduced, proinflammatory factors are down-regulated, and immunoregulatory factors are up-regulated. The ALA has a direct treatment effect on local skin lesions, is highly in line with the core requirements of'improving skin lesion appearance and relieving epidermal hyperplasia 'of psoriasis patients in clinic, improves the overall treatment effect through'local and whole body' dual anti-inflammatory effects, and is expected to be developed into an external or systemic medicine in the future to be used for treating mild to moderate psoriasis.

The application discloses application of anti-IGFBP7 antibodies in treating skin diseases, belongs to the technical field of psoriasis treatment, and discloses application of anti-IGFBP7 antibodies in preparation of a medicament for treating psoriasis, wherein the medicament is used for reducing and treating psoriasis-like inflammation by inhibiting expression of IGFBP7 in blood vessels of skin of a psoriasis patient. After the anti-IGFBP7 antibodies are used, psoriasis inflammation is reduced, meanwhile, epidermal thickness of a psoriasis patient is reduced, erythema formation is inhibited, and the generation of scales is reduced. In protecting vascular barrier function and treating psoriasis, the anti-IGFBP7 antibodies have a good medicinal prospect.